Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 19;30(3):283-8.
doi: 10.1038/nbt.2121.

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

Elisabet Wahlberg  1 , Tobias Karlberg, Ekaterina Kouznetsova, Natalia Markova, Antonio Macchiarulo, Ann-Gerd Thorsell, Ewa Pol, Åsa Frostell, Torun Ekblad, Delal Öncü, Björn Kull, Graeme Michael Robertson, Roberto Pellicciari, Herwig Schüler, Johan Weigelt
Affiliations

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

Elisabet Wahlberg et al. Nat Biotechnol. .

Abstract

Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clinical trials as cancer therapeutics, yet the specificity of many of these compounds is unknown. Here we evaluated a series of 185 small-molecule inhibitors, including research reagents and compounds being tested clinically, for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2. Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these molecules lack specificity and have promiscuous inhibitory activity. We also determined X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes. In addition to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.

PubMed Disclaimer

Comment in

  • Profiling PARP inhibitors.
    Jones P. Jones P. Nat Biotechnol. 2012 Mar 7;30(3):249-50. doi: 10.1038/nbt.2138. Nat Biotechnol. 2012. PMID: 22398621 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Expert Opin Ther Pat. 2009 Oct;19(10):1377-400 - PubMed
    1. J Pharmacol Exp Ther. 2009 Apr;329(1):150-8 - PubMed
    1. J Natl Cancer Inst. 2004 Jan 7;96(1):56-67 - PubMed
    1. J Pharmacol Exp Ther. 2003 Jun;305(3):943-9 - PubMed
    1. J Med Chem. 2009 May 14;52(9):3108-11 - PubMed

Publication types

MeSH terms

LinkOut - more resources